• 1. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 4. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 5. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383

Professional Introduction to Compound with CAS No. 1354001-60-7 and Product Name: 1-((R)-3-Isopropylamino-pyrrolidin-1-yl)-ethanone

The compound with the CAS number 1354001-60-7 and the product name 1-((R)-3-Isopropylamino-pyrrolidin-1-yl)-ethanone represents a significant advancement in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique structural framework, has garnered considerable attention due to its potential applications in drug discovery and molecular pharmacology. The presence of a chiral center at the (R)-3-isopropylamino-pyrrolidin-1-yl moiety makes it a particularly intriguing subject for further investigation, as stereochemistry plays a crucial role in the biological activity and efficacy of many therapeutic agents.

In recent years, there has been a growing interest in the development of novel heterocyclic compounds that exhibit potent biological activity. The pyrrolidine scaffold, a six-membered nitrogen-containing heterocycle, is well-known for its versatility and prevalence in biologically active molecules. The specific modification of the pyrrolidine ring with an isopropylamino group and an acetyl moiety in 1-((R)-3-Isopropylamino-pyrrolidin-1-yl)-ethanone introduces unique functional properties that may contribute to its pharmacological profile. This compound has been studied for its potential role in modulating various biological pathways, particularly those involving enzyme inhibition and receptor interaction.

One of the most compelling aspects of this compound is its structural similarity to known pharmacophores that have demonstrated efficacy in clinical settings. The (R)-configuration of the isopropylamino group is particularly noteworthy, as enantiomeric purity is often a critical factor in determining the therapeutic outcome of a drug candidate. The synthesis and characterization of this compound have been refined through advanced organic chemistry techniques, ensuring high yield and purity necessary for rigorous biological testing.

Recent studies have highlighted the importance of pyrrolidine derivatives in the development of drugs targeting neurological disorders, cardiovascular diseases, and inflammatory conditions. The acetyl group in 1-((R)-3-Isopropylamino-pyrrolidin-1-yl)-ethanone provides a versatile handle for further chemical modification, allowing researchers to explore analogues with enhanced pharmacokinetic properties or altered binding affinities. This flexibility makes it an attractive scaffold for medicinal chemists seeking to develop next-generation therapeutics.

The biological activity of this compound has been preliminarily assessed through in vitro assays, where it has shown promising interactions with specific enzymes and receptors. For instance, preliminary data suggest that it may inhibit certain kinases involved in cell signaling pathways relevant to cancer progression. Additionally, its ability to modulate neurotransmitter receptors has prompted investigations into its potential as a treatment for neurodegenerative diseases such as Alzheimer's and Parkinson's. These findings underscore the compound's significance as a lead molecule for further drug development.

The synthesis of 1-((R)-3-Isopropylamino-pyrrolidin-1-yl)-ethanone involves multi-step organic reactions that require precise control over reaction conditions to ensure optimal yield and enantiomeric purity. Advanced techniques such as asymmetric hydrogenation and chiral resolution have been employed to achieve the desired stereochemical configuration. The robustness of the synthetic route ensures scalability, which is essential for large-scale production and clinical trials.

In conclusion, the compound with CAS number 1354001-60-7 and product name 1-((R)-3-Isopropylamino-pyrrolidin-1-yl)-ethanone represents a promising candidate for further exploration in pharmaceutical research. Its unique structural features, combined with preliminary biological activity data, make it a valuable asset in the quest for novel therapeutics. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in addressing some of today's most pressing medical challenges.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)